Abstracts tagged "Antibodies"

Abstract Number: 2318 • 2017 ACR/ARHP Annual Meeting
Measurement of Serum Infliximab and Antibody Levels As an Adjunct to Clinical Decision Making Regarding Infliximab Therapy
Eileen Pagano¹, Myriam Kline² and B. Anne Eberhard³, ¹Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ²Biostatistics Unit, Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ³Pediatric Rheumatology, Cohen Children's Medical Center of New York, Lake Success, NY
Background/Purpose: Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-a). It is known to be effective and often used in the…
Abstract Number: 2876 • 2017 ACR/ARHP Annual Meeting
Analysis of Autoantibody Reactivity to the Complete Human Peptidome By Phage Immunoprecipitation Sequencing Does Not Identify a Predominant Novel Autoantibody in Sjogren’s Syndrome
Tiezheng Yuan¹, Michelle Petri², Alan N. Baer³ and H. Benjamin Larman¹, ¹Pathology (Immunology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: An unbiased and comprehensive approach to the analysis of Sjögren’s syndrome (SS) antibody repertoires would provide important data on its pathogenesis. Phage ImmunoPrecipitation sequencing…
Abstract Number: 132 • 2017 ACR/ARHP Annual Meeting
Occupational Physical Workload and Development of Anti-Collagen Type II Antibodies in Rheumatoid Arthritis Patients
Pingling Zeng¹, Lars Alfredsson², Lars Klareskog³, Mohammed Mullazehi⁴, Saedis Saevarsdottir⁵, Camilla Bengtsson⁶ and Johan Rönnelid⁷, ¹Institute of Environmental Medicine, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ²The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Immunology, Genetics and Pathology,Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ⁵Karolinska Institute and Karonlinska University Hospital, Stockholm, Sweden, ⁶Inst of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden
Background/Purpose: We have previously observed an association between exposure to occupational physical workload (PW) and risk of developing rheumatoid arthritis (RA)[1].We posit that PW could…
Abstract Number: 521 • 2017 ACR/ARHP Annual Meeting
Update on the Clinical Phase 1 and Phase 2 Trials Investigating the Fully Human Immunocytokine Dekavil (F8IL10) in Patients with Rheumatoid Arthritis
Mauro Galeazzi¹, Gian Domenico Sebastiani², Jürgen Wollenhaupt³, Jean Dudler⁴, Christof Specker⁵, Reinhard Voll⁶, Pascal Zufferey⁷, Piercarlo Sarzi Puttini⁸, Ombretta Viapiana⁹ and Franziska Bootz¹⁰, ¹Rheumatology, University Hospital of Siena, Siena, Italy, ²Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁴Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, ⁵Rheumatology, St. Josef Krankenhaus, Universitätsklinikum Essen, Esssen, Germany, ⁶Clinic for Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Freiburg, Germany, ⁷Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ⁸Rheumatology, Luigi Sacco Hospital, Milan, Italy, ⁹University Hospital Verona, Verona, Italy, ¹⁰Clinical Department, Philochem AG (Philogen Group), Otelfingen, Switzerland
Background/Purpose: The antibody-based targeted pharmacodelivery of cytokines by means of immunocytokines has the potential to enhance therapeutic activity at the site of disease while sparing…
Abstract Number: 944 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients
Devon Charlton¹, Maureen Laffoon², Thomas A. Medsger Jr.³ and Robyn T. Domsic⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Anti-Th/To antibody is an autoantibody associated with systemic sclerosis (SSc), occurring in 5-10% of patients. To date, only relatively small case series have described…
Abstract Number: 1437 • 2016 ACR/ARHP Annual Meeting
Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis
Aranzazu Mediero¹, Tuere Wilder², Bhama Ramkhelawon³, Kathryn Moore³ and Bruce Cronstein⁴, ¹Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, ²Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, ⁴Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and destruction of joints. Netrin-1, a laminin-like matrix protein that acts as a…
Abstract Number: 1667 • 2016 ACR/ARHP Annual Meeting
Diagnostic Value of Anti-CD74 Antibodies in Axial Spondyloarthritis: Results from a Population with Low HLA-B27 Prevalence Background
Nelly Ziade¹, Fouad Fayad¹, Iyad Mallak², Georges Merheb³, Torsten Witte⁴ and Xenofon Baraliakos⁵, ¹Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Radiology, Hotel-Dieu de France and Saint-Joseph University, Beirut, Lebanon, ³Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, ⁴Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ⁵Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is still frequently diagnosed late and its pathogenesis is still unclear. Although a strong genetic association of axSpA with HLA-B27 is…
Abstract Number: 1876 • 2016 ACR/ARHP Annual Meeting
Prevalence of Anti-RNA Polymerase III IgG Antibody in a Cohort of Patients with Delayed Wound Healing
Christian Geier¹, Sean McNish² and Victoria K. Shanmugam², ¹Department of Medicine, The George Washington University, Washington, DC, ²Division of Rheumatology, The George Washington University, Washington, DC
Prevalence of Anti-RNA Polymerase III IgG Antibody in a Cohort of Patients with Delayed Wound Healing Background/Purpose: Anti-RNA polymerase III IgG antibody (Pol3) is associated…
Abstract Number: 2454 • 2016 ACR/ARHP Annual Meeting
Cohort of Pregnant Women with Ro/La Antibodies: Risk of Fetal Third Degree Atrioventricular Block and Use of Hydroxychloroquine
Florencia Beatriz Mollerach¹, Marina Scolnik², Luis J. Catoggio² and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina
Background/Purpose: Third degree atrioventricular block(AVB), a rare congenital complication, duplicate-triplicate frequency up to 2% when Ro/La maternal antibodies are present. Incidence rises to 17-20% in…
Abstract Number: 2535 • 2016 ACR/ARHP Annual Meeting
Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Chamaida Plasencia-Rodriguez¹, Ana Martínez², Alejandro Villalba³, Teresa Jurado⁴, Eva Olariaga-Merida⁵, Araceli Mezcua⁶, Diana Peiteado³, Gema Bonilla³, Laura Nuño³, Alejandro Balsa¹ and Dora Pascual-Salcedo², ¹Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁵Immunology, University Hospital La Paz, Madrid, Spain, ⁶Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: Several factors influence pharmacokinetics of TNFinhibitors (TNFi). One relevant factor is the formation of anti drug- antibodies (ADA) associated with low drug levels and…
Abstract Number: 2682 • 2016 ACR/ARHP Annual Meeting
How Does Primary Sjogren Syndrome Present in Biopsy-Proven Patients without Circulating Ro/La Autoantibodies? Characteristics at Diagnosis of 2073 Patients from the SjöGren Big Data Project
Pilar Brito-Zerón^1,2,3, Nihan Acar-Denizli⁴, Margit Zeher⁵, Astrid Rasmussen⁶, Raphaele Seror⁷, Elke Theander⁸, Xiaomei Li⁹, Chiara Baldini¹⁰, Jacques-Eric Gottenberg¹¹, Debashish Danda¹², Luca Quartuccio¹³, Roberta Priori^14,15, Gabriela Hernandez-Molina¹⁶, Aike A. Kruize¹⁷, Valeria Valim¹⁸, Marika Kvarnström¹⁹, Damien Sene²⁰, Roberto Gerli²¹, Sonja Praprotnik²², David A. Isenberg²³, Roser Solans²⁴, Maureen Rischmueller²⁵, Seung-Ki Kwok²⁶, Gunnel Nordmark²⁷, Yasunori Suzuki²⁸, Roberto Giacomelli²⁹, Valerie Devauchelle-Pensec³⁰, Michele Bombardieri³¹, Benedikt Hofauer³², Hendrika Bootsma³³, Johan G. Brun³⁴, Guadalupe Fraile³⁵, Steven E. Carsons³⁶, Tamer Gheita³⁷, Jacques Morel³⁸, Cristina F. Vollenweider³⁹, Fabiola Atzeni⁴⁰, Soledad Retamozo⁴¹, Ildike-Fanny Horvath⁵, Kathy Sivils⁶, Thomas Mandl^42,43, Pulukool Sandhya¹², Salvatore De Vita⁴⁴, Jorge Sánchez-Guerrero⁴⁵, Eefje van der Heijden¹⁷, Virginia Moça Trevisano⁴⁶, Marie Wahren-Herlenius¹⁹, Xavier Mariette⁷, Manuel Ramos-Casals^3,47,48 and EULAR-SS Task Force Big Data Consortium (ASSES, GEAS-SEMI, EULAR), ¹Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁴Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Turkey, Istabul, Turkey, ⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ⁷Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, ⁸Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Malmö, Sweden, ⁹Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, ¹⁰Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹¹Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France, ¹²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹³Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, ¹⁴Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ¹⁵Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ¹⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ¹⁷Department of Rheumatology & Clinical Immunology, Medical Center Utrecht, The Netherlands, Utrecht, Netherlands, ¹⁸Rheumatology, Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, ¹⁹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²⁰Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris, 2, Paris, France, Paris, France, ²¹Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Italy, Perugia, Italy, ²²Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ²⁴Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁵Department of Rheumatology, School of Medicine, The University of Western Australia, Crawley, Australia, Crawley, Australia, ²⁶[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²⁷Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ²⁸Division of Rheumatology , Kanazawa University Hospital , Kanazawa , Ishikawa , Japan, Ishikawa, Japan, ²⁹Clinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy, L'Aquila, Italy, ³⁰Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³¹Willian Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, QMUL, UK, London, United Kingdom, ³²Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität München, München, Germany, München, Germany, ³³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands, ³⁴Department of Clinical Science, University of Bergen. Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, Bergen, Norway, ³⁵Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, ³⁶Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY, ³⁷Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Egypt, Cairo, Egypt, ³⁸Department of Rheumatology, Teaching hospital and University of Montpellier, France, Montpellier, France, ³⁹Rheumatology, German Hospital, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴⁰IRCCS Galeazzi Orthopedic Institute, Milan, Italy, Milan, Italy, ⁴¹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ⁴²Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, ⁴³Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Lund, Sweden, ⁴⁴Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, ⁴⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ⁴⁶Federal University of São Paulo, Sao Paulo, Brazil, San Paulo, Brazil, ⁴⁷Sjögren Syndrome Research Group (AGAUR), Barcelona, Spain, ⁴⁸Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain
Background/Purpose: To analyse the main characteristics of patients with primary Sjögren syndrome (SjS) with focal lymphocytic sialadenitis (FLS) unrelated to the presence of circulating anti-Ro/La…
Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
Louis Bessette¹, Majed Khraishi², Alan J Kivitz³, Arunan Kaliyaperumal⁴, Rama Grantab⁵, Melanie Poulin-Costello⁵, Maya Isaila⁵ and David Collier⁴, ¹Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…
Abstract Number: 2687 • 2016 ACR/ARHP Annual Meeting
Prevalence of Abortions and Fetal Atrioventricular Block in Patients with Positive ANTI-RO and ANTI-La Antibodies
Isabel Martinez Cordellat¹, Francisco Miguel Ortiz-Sanjuán¹, Jose Ivorra Cortes¹, Luis Gonzalez Puig¹, Inmaculada Chalmeta Verdejo¹, Irene Calabuig Sais², Elena Grau Garcia^1,3, Carlos Feced Olmos¹, Eztizen Labrador Sanchez¹, Karla Arevalo Ruales¹, Rosa Negueroles Albuixech¹, Jorge Fragio Gil¹, Jose Luis Valero Sanz¹, Cristina Alcañiz Escandell^1,3, Carmen Najera Herranz¹, Gema Poveda Marin^1,3 and Jose Andres Roman Ivorra^1,2,3, ¹Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Universidad Católica de Valencia, Valencia, Spain, ³IIS La Fe, Valencia, Spain
Background/Purpose: anti-SSA/Ro and/or anti-SSB/La antibodies and to evaluate the prevalence of abortions and neonatal mortality. We included 162 patients with positive anti-SSA/Ro and/or…
Abstract Number: 613 • 2016 ACR/ARHP Annual Meeting
Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients
Alejandro Balsa¹, Raimon Sanmarti², José Rosas³, Susana Gomez Castro⁴, Ana Cabez⁴, Victor Martin⁴ and María Montoro⁴, ¹Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴Pfizer, Madrid, Spain
Abstract Immunogenicity of anti-TNF therapies in Patients with inflammatory rheumatic Diseases and secondary failure: a multicentre study of 570 patients. Background/Purpose: The treatment of…
Abstract Number: 2826 • 2016 ACR/ARHP Annual Meeting
Clinical Utility of Circulating Anti-N-Methyl-D-Aspartate Receptor Subunits NR2A/B Antibody for the Diagnosis of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Sjogren’s Syndrome: An Updated Meta-Analysis
Sen Hee Tay¹, Anna-Marie Fairhurst² and Anselm Mak¹, ¹Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, Singapore, ²Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore
Background/Purpose: Neuropsychiatric (NP) events are found in patients with rheumatic diseases, commonly in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). The standard nomenclature and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].